ArticleMedicine2026

Cost-effectiveness analysis of Enfortumab vedotin and pembrolizumab for advanced urothelial carcinoma.

Hao Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.